- Employers are dropping GLP-1 weight-loss coverage
Three 2026 surveys point the same way. A Business Group on Health survey found 60% of large employers now cover GLP-1s for weight loss, down from 72% in 2025, with Cigna and PwC already out and PepsiCo and Starbucks following in October. Employers Health says about 65% of its roughly 500 self-insured clients now exclude them. Surveys use different employer groups, so the numbers aren’t directly comparable.
What it means for patients: If your coverage changed, you still have options. BeLite consultations are free, and we can walk through costs with you.
Source: KFF Health News, Sept 8, 2026 · Managed Healthcare Executive, Sept 23, 2026
- Tirzepatide and semaglutide linked to lower dementia diagnoses in diabetes
A real-world study of people with type 2 diabetes found tirzepatide had a lower two-year dementia rate than semaglutide (HR 0.69) or SGLT2 inhibitors (HR 0.66); semaglutide also beat SGLT2 inhibitors (HR 0.71). This is observational, not a randomized trial, and the authors call it hypothesis-generating.
What it means for patients: Interesting, but not a reason to switch medications. Results in people without diabetes haven’t been studied.
Source: Younis et al., Diabetes Res Clin Pract 2026
- GLP-1 prescribing to young children is rising fast
A Pediatrics study published Sept 4 found annual GLP-1 prescribing among children 8–11 with obesity rose from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase. STAT News reports trials now include children as young as 6. No GLP-1 is FDA-approved for obesity under age 12.
What it means for patients: For parents, this is a decision for a pediatrician or pediatric obesity specialist, not a general recommendation.
Source: Orandi et al., Pediatrics 2026 · STAT News, Sept 15, 2026
- Watch list: CagriSema still awaiting an FDA decision
Novo Nordisk filed in December 2025 and a decision is expected in the fourth quarter of 2026. As of October 6 there is no approval. Retatrutide is not expected to be filed until Q1 2027 and can’t legally be prescribed or compounded.
What it means for patients: If anyone tells you either drug is available now, be skeptical. See our own CagriSema REDEFINE trials review.
Source: FDA status checked Oct 6, 2026
Go deeper
Full articles on items 1–3 are in this week’s Research Brief. Our existing guides: Our Medications · What happens after stopping Wegovy or Zepbound · Does tirzepatide lower cardiovascular risk?
[Publishing note: once the three new articles are live, link items 1–3 to them directly.]
How BeLite Can Help
BeLite Medical Center has provided physician-supervised weight management in Fairfax, Virginia since 1995. New-patient consultations are free. Call or text (703) 359-9200.
Medical disclaimer: This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed physician before starting, stopping, or changing any medication.
BeLite can help patients translate emerging obesity-medicine evidence into an individualized plan that considers efficacy, tolerability, nutrition, muscle preservation, long-term maintenance, and access.BeLite Medical Center has provided physician-supervised medical weight management in Fairfax, Virginia since 1995. Our clinic offers in-person medical supervision — with the ability to adjust medications and monitor your progress in real time — that fully virtual services cannot match.Booking appointments is simple with our online scheduling portal, available 24/7. You can also call or text us at (703) 359-9200, or email belitemed@gmail.com. We offer free consultations for new patients — if you choose not to enroll, there is no charge. We serve patients across Virginia, Maryland, Washington D.C., the DMV area, Pennsylvania, and West Virginia. Patients do not sign treatment contracts and can stop coming at any time
Medical Disclaimer
This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Readers should not use this information to diagnose or treat a medical or health condition without consulting an appropriately qualified healthcare professional. Any reliance on the information in this blog is at the readers own risk. Individual weight loss results vary based on personal health status and adherence to medical advice. No doctor-patient relationship is created by accessing or reading this content.
Reviewed by Richard Rothman, MD, PhD — Medical Director, BeLite Medical Center.
About BeLite Medical Center
BeLite Medical Center in Northern, VA helps you reach your weight loss goals.
